Mirikizumab

Therapeutic indications

Mirikizumab is indicated for:

Moderately to severely active ulcerative colitis

Population group: only adults (18 years old or older)

Mirikizumab is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic treatment.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

300 mg by intravenous infusion at weeks 0, 4, 8 and thereafter 200 mg by subcutaneous injection at week 12 and every 4 weeks

Contraindications

Mirikizumab is contraindicated in the following cases:

Pregnancy

Clinically important active infections

Infectious disease

Vaccines

< Previous: Overview

Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.